CN1706865A - Branched polyglycol-amino acid oligopeptide and its active derivative and medicinal composition - Google Patents
Branched polyglycol-amino acid oligopeptide and its active derivative and medicinal composition Download PDFInfo
- Publication number
- CN1706865A CN1706865A CNA2004100480166A CN200410048016A CN1706865A CN 1706865 A CN1706865 A CN 1706865A CN A2004100480166 A CNA2004100480166 A CN A2004100480166A CN 200410048016 A CN200410048016 A CN 200410048016A CN 1706865 A CN1706865 A CN 1706865A
- Authority
- CN
- China
- Prior art keywords
- polyoxyethylene glycol
- amino acid
- compound
- group
- oligopeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 58
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims description 13
- 239000003814 drug Substances 0.000 claims abstract description 63
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 16
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 14
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims abstract description 11
- -1 polyoxyethylene Polymers 0.000 claims description 133
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 118
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 90
- 229940024606 amino acid Drugs 0.000 claims description 63
- 229940079593 drug Drugs 0.000 claims description 52
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 44
- 239000000126 substance Substances 0.000 claims description 43
- 239000000243 solution Substances 0.000 claims description 39
- 235000001014 amino acid Nutrition 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 36
- 229960002989 glutamic acid Drugs 0.000 claims description 31
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 30
- 239000004471 Glycine Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000000499 gel Substances 0.000 claims description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 102000004860 Dipeptidases Human genes 0.000 claims description 16
- 108090001081 Dipeptidases Proteins 0.000 claims description 16
- 108010016626 Dipeptides Proteins 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 13
- 229930182817 methionine Natural products 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 9
- 229940059574 pentaerithrityl Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229920002643 polyglutamic acid Polymers 0.000 claims description 8
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 6
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 claims description 5
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 5
- 150000001263 acyl chlorides Chemical class 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 125000005647 linker group Chemical group 0.000 claims description 5
- 239000002777 nucleoside Substances 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims description 4
- 229930013930 alkaloid Natural products 0.000 claims description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- 125000003835 nucleoside group Chemical group 0.000 claims description 4
- 150000002989 phenols Chemical class 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- 235000007586 terpenes Nutrition 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- UCMLAGLRLOPBAX-PRRDBKRISA-N (3as,4r,7s,7ar)-3a,7a-dimethyl-2-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-4,5,6,7-tetrahydro-octahydro-1h-4,7-epoxyisoindole-1,3-dione Chemical compound C1=C(OC(F)(F)F)C=C2SC(N3C(=O)[C@]4(C)[C@H]5CC[C@H](O5)[C@@]4(C3=O)C)=NC2=C1 UCMLAGLRLOPBAX-PRRDBKRISA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims description 3
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229960003720 enoxolone Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 150000004053 quinones Chemical class 0.000 claims description 3
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims description 3
- 229930190376 scutellarin Natural products 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 239000003566 sealing material Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 229920000151 polyglycol Polymers 0.000 abstract description 2
- 239000010695 polyglycol Substances 0.000 abstract description 2
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 22
- 239000001257 hydrogen Substances 0.000 description 22
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000002202 Polyethylene glycol Substances 0.000 description 17
- 229920001223 polyethylene glycol Polymers 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000001291 vacuum drying Methods 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 4
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 4
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Surgery (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (28)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100480166A CN100475837C (en) | 2004-06-11 | 2004-06-11 | Branched polyglycol-amino acid oligopeptide and active derivative and medicinal composition thereof |
PCT/CN2005/000834 WO2005121181A1 (en) | 2004-06-11 | 2005-06-10 | Multi-drop tree branching polyethylene glycol-oligopeptides and active derivates and pharmaceutical compounds there of |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100480166A CN100475837C (en) | 2004-06-11 | 2004-06-11 | Branched polyglycol-amino acid oligopeptide and active derivative and medicinal composition thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1706865A true CN1706865A (en) | 2005-12-14 |
CN100475837C CN100475837C (en) | 2009-04-08 |
Family
ID=35503014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100480166A Expired - Lifetime CN100475837C (en) | 2004-06-11 | 2004-06-11 | Branched polyglycol-amino acid oligopeptide and active derivative and medicinal composition thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100475837C (en) |
WO (1) | WO2005121181A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052428A1 (en) * | 2006-10-24 | 2008-05-08 | Beijing Jenkem Technology Co. Ltd | Preparation method and conjugate with drug molecule thereof |
WO2010060260A1 (en) * | 2008-11-03 | 2010-06-03 | 北京键凯科技有限公司 | Novel multi-arm polyethylene glycol, preparation method and uses thereof |
WO2011075953A1 (en) * | 2009-12-25 | 2011-06-30 | 天津键凯科技有限公司 | Multi-arm polyethylene glycol derivatives, conjugates and gels of drugs and the same |
CN102266566A (en) * | 2010-06-03 | 2011-12-07 | 中国人民解放军军事医学科学院毒物药物研究所 | Magnetic compound, and preparation method and purpose thereof |
CN103083680A (en) * | 2011-11-07 | 2013-05-08 | 北京键凯科技有限公司 | Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition |
CN103857702A (en) * | 2011-10-03 | 2014-06-11 | 南洋理工大学 | Cationic peptidopolysaccharides with excellent broad- spectrum antimicrobial activities and high selectivity |
WO2014114262A1 (en) * | 2013-01-28 | 2014-07-31 | 天津键凯科技有限公司 | Water soluble polymer-amino acid oligopeptide-medicine combination, preparation method therefore, and use thereof |
CN104448295A (en) * | 2013-12-02 | 2015-03-25 | 北京键凯科技有限公司 | Polyethylene glycol-cactus oligopeptide bonded rapamycin derivative |
CN105017522A (en) * | 2015-07-20 | 2015-11-04 | 湖南华腾制药有限公司 | Polyethylene glycol-modified unnatural amino acid preparation method |
WO2017114495A1 (en) * | 2015-12-30 | 2017-07-06 | 北京大学 | Polyaminoacid, protein-polyaminoacid conjugate and preparation method therefor |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
WO2017210963A1 (en) * | 2016-06-07 | 2017-12-14 | 北京键凯科技有限公司 | Peg linker and ligand drug conjugate |
CN108003342A (en) * | 2018-02-02 | 2018-05-08 | 中国科学院长春应用化学研究所 | Polyaminoacid, its preparation method and load medicinal gel |
WO2018177055A1 (en) * | 2017-03-30 | 2018-10-04 | 北京键凯科技股份有限公司 | Method for preparing y-branched hydrophilic polymer carboxylic acid derivative |
CN108659227A (en) * | 2017-03-30 | 2018-10-16 | 北京键凯科技股份有限公司 | A kind of preparation method of the hydrophilic polymer carboxylic acid derivates of y-branch |
CN109897179A (en) * | 2019-04-02 | 2019-06-18 | 中国科学院长春应用化学研究所 | A kind of poly- (Pidolidone ester) block copolymer of multi-arm polyethylene glycol-and its preparation method and application |
CN111936550A (en) * | 2018-03-29 | 2020-11-13 | 日油株式会社 | Degradable polyethylene glycol derivative |
CN112251484A (en) * | 2020-10-26 | 2021-01-22 | 江南大学 | Method for preparing glycine oligopeptide-polyethylene glycol copolymer under catalysis of lipase |
CN114450324A (en) * | 2019-09-26 | 2022-05-06 | 日油株式会社 | Heterobifunctional monodisperse polyethylene glycols with peptide linkers |
CN115975182A (en) * | 2023-01-10 | 2023-04-18 | 深圳市乐土生物医药有限公司 | Amino acid copolymer and application thereof |
CN116178733A (en) * | 2023-03-03 | 2023-05-30 | 浙江博美生物技术有限公司 | Branched monodisperse PEG derivative based on trifunctional amino acid, preparation method and application |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
CN101321806B (en) | 2005-12-05 | 2011-01-26 | 日东电工株式会社 | Polyglutamate-amino acid conjugates and methods |
EP1957089A4 (en) * | 2005-12-06 | 2012-06-20 | Tyco Healthcare | Carbodiimide crosslinking of functionalized polethylene glycols |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
EP2019691B1 (en) | 2006-05-15 | 2020-08-12 | Massachusetts Institute of Technology | Polymers for functional particles |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
EP2144600A4 (en) | 2007-04-04 | 2011-03-16 | Massachusetts Inst Technology | Poly (amino acid) targeting moieties |
BRPI0817664A2 (en) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanoparticles, method for preparing nanoparticles and method for therapeutically or prophylactically treating an individual |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
ITRM20080551A1 (en) * | 2008-10-15 | 2010-04-16 | Univ Catania | AMPHIFYL DERIVATIVES OF POLYOSSIETHYLENE GLYCOL (PEG), PREPARATION PROCEDURE AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL SYSTEMS. |
CN108264538B (en) * | 2017-01-04 | 2023-08-29 | 辽宁药联制药有限公司 | Solid Phase Synthesis Method of Aspartic Acid Condensate |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1251530A3 (en) * | 2001-04-16 | 2004-12-29 | Shipley Company LLC | Dielectric laminate for a capacitor |
CN1176137C (en) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine |
CN100475269C (en) * | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | Binding agent of hydrophilic polymer-glutamic acid oligopeptide and medicinal molecular, composition containing said binding agent and use thereof |
CN1254496C (en) * | 2002-05-30 | 2006-05-03 | 中国科学院过程工程研究所 | Method of preparing branched polyethylene glycol |
-
2004
- 2004-06-11 CN CNB2004100480166A patent/CN100475837C/en not_active Expired - Lifetime
-
2005
- 2005-06-10 WO PCT/CN2005/000834 patent/WO2005121181A1/en active Application Filing
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101168594B (en) * | 2006-10-24 | 2011-07-27 | 北京键凯科技有限公司 | Polyglycol active derivative with oligopeptide as framework, preparation method thereof and conjugate of with pharmaceutical molecule |
WO2008052428A1 (en) * | 2006-10-24 | 2008-05-08 | Beijing Jenkem Technology Co. Ltd | Preparation method and conjugate with drug molecule thereof |
WO2010060260A1 (en) * | 2008-11-03 | 2010-06-03 | 北京键凯科技有限公司 | Novel multi-arm polyethylene glycol, preparation method and uses thereof |
US11208530B2 (en) | 2008-11-03 | 2021-12-28 | Xuan Zhao | Multi-arm polyethylene glycol, preparation method and uses thereof |
CN103755949B (en) * | 2009-12-25 | 2016-04-13 | 天津键凯科技有限公司 | Multi-arm polyethylene glycol derivative and with the binding substances of medicine and gel |
WO2011075953A1 (en) * | 2009-12-25 | 2011-06-30 | 天津键凯科技有限公司 | Multi-arm polyethylene glycol derivatives, conjugates and gels of drugs and the same |
US9555123B2 (en) | 2009-12-25 | 2017-01-31 | Jenkem Technology Co., Ltd. Tianjin Branch | Multi-arm polyethylene glycol derivatives, conjugates and gels of pharmaceuticals and the same |
WO2011150671A1 (en) * | 2010-06-03 | 2011-12-08 | 中国人民解放军军事医学科学院毒物药物研究所 | Magnetic composite, preparation method and use thereof |
CN102266566B (en) * | 2010-06-03 | 2013-06-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Magnetic compound, and preparation method and purpose thereof |
CN102266566A (en) * | 2010-06-03 | 2011-12-07 | 中国人民解放军军事医学科学院毒物药物研究所 | Magnetic compound, and preparation method and purpose thereof |
CN103857702B (en) * | 2011-10-03 | 2018-01-26 | 南洋理工大学 | Cationic peptide polysaccharide with excellent broad spectrum antimicrobial acivity and high selectivity |
CN103857702A (en) * | 2011-10-03 | 2014-06-11 | 南洋理工大学 | Cationic peptidopolysaccharides with excellent broad- spectrum antimicrobial activities and high selectivity |
CN103083680B (en) * | 2011-11-07 | 2014-12-24 | 北京键凯科技有限公司 | Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition |
EP2777713A4 (en) * | 2011-11-07 | 2015-08-19 | Jenkem Technology Co Ltd Beijing | Polyethylene glycol-amino acid oligopeptide-irinotecan drug conjugate and drug composition thereof |
WO2013067767A1 (en) * | 2011-11-07 | 2013-05-16 | 北京键凯科技有限公司 | Polyethylene glycol-amino acid oligopeptide-irinotecan drug conjugate and drug composition thereof |
CN103083680A (en) * | 2011-11-07 | 2013-05-08 | 北京键凯科技有限公司 | Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition |
WO2014114262A1 (en) * | 2013-01-28 | 2014-07-31 | 天津键凯科技有限公司 | Water soluble polymer-amino acid oligopeptide-medicine combination, preparation method therefore, and use thereof |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
CN104448295A (en) * | 2013-12-02 | 2015-03-25 | 北京键凯科技有限公司 | Polyethylene glycol-cactus oligopeptide bonded rapamycin derivative |
CN105017522A (en) * | 2015-07-20 | 2015-11-04 | 湖南华腾制药有限公司 | Polyethylene glycol-modified unnatural amino acid preparation method |
WO2017114495A1 (en) * | 2015-12-30 | 2017-07-06 | 北京大学 | Polyaminoacid, protein-polyaminoacid conjugate and preparation method therefor |
CN107469089A (en) * | 2016-06-07 | 2017-12-15 | 北京键凯科技股份有限公司 | A kind of PEG connexons and aglucon drug conjugates |
WO2017210963A1 (en) * | 2016-06-07 | 2017-12-14 | 北京键凯科技有限公司 | Peg linker and ligand drug conjugate |
US11759528B2 (en) | 2016-06-07 | 2023-09-19 | Jenkem Technology Co., Ltd. (Beijing) | Peg linker and ligand drug conjugate |
CN107469089B (en) * | 2016-06-07 | 2022-01-07 | 北京键凯科技股份有限公司 | PEG connector and aglucon drug conjugate |
WO2018177055A1 (en) * | 2017-03-30 | 2018-10-04 | 北京键凯科技股份有限公司 | Method for preparing y-branched hydrophilic polymer carboxylic acid derivative |
CN108659227A (en) * | 2017-03-30 | 2018-10-16 | 北京键凯科技股份有限公司 | A kind of preparation method of the hydrophilic polymer carboxylic acid derivates of y-branch |
US11359089B2 (en) | 2017-03-30 | 2022-06-14 | Jenkem Technology Co., Ltd. (Beijing) | Method for preparing Y-branched hydrophilic polymer carboxylic acid derivative |
CN108003342A (en) * | 2018-02-02 | 2018-05-08 | 中国科学院长春应用化学研究所 | Polyaminoacid, its preparation method and load medicinal gel |
CN111936550A (en) * | 2018-03-29 | 2020-11-13 | 日油株式会社 | Degradable polyethylene glycol derivative |
CN111936550B (en) * | 2018-03-29 | 2023-11-28 | 日油株式会社 | Decomposable polyethylene glycol derivative |
CN109897179B (en) * | 2019-04-02 | 2021-08-17 | 中国科学院长春应用化学研究所 | Multi-arm polyethylene glycol-poly (L-glutamate) block copolymer, and preparation method and application thereof |
CN109897179A (en) * | 2019-04-02 | 2019-06-18 | 中国科学院长春应用化学研究所 | A kind of poly- (Pidolidone ester) block copolymer of multi-arm polyethylene glycol-and its preparation method and application |
CN114450324A (en) * | 2019-09-26 | 2022-05-06 | 日油株式会社 | Heterobifunctional monodisperse polyethylene glycols with peptide linkers |
CN114450324B (en) * | 2019-09-26 | 2024-02-27 | 日油株式会社 | Heterobifunctional monodisperse polyethylene glycols with peptide linkers |
CN112251484B (en) * | 2020-10-26 | 2022-05-24 | 江南大学 | Method for preparing glycine oligopeptide-polyethylene glycol copolymer under catalysis of lipase |
CN112251484A (en) * | 2020-10-26 | 2021-01-22 | 江南大学 | Method for preparing glycine oligopeptide-polyethylene glycol copolymer under catalysis of lipase |
CN115975182A (en) * | 2023-01-10 | 2023-04-18 | 深圳市乐土生物医药有限公司 | Amino acid copolymer and application thereof |
CN116178733A (en) * | 2023-03-03 | 2023-05-30 | 浙江博美生物技术有限公司 | Branched monodisperse PEG derivative based on trifunctional amino acid, preparation method and application |
CN116178733B (en) * | 2023-03-03 | 2023-08-01 | 浙江博美生物技术有限公司 | Branched monodisperse PEG derivative based on trifunctional amino acid, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
WO2005121181A1 (en) | 2005-12-22 |
CN100475837C (en) | 2009-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1706865A (en) | Branched polyglycol-amino acid oligopeptide and its active derivative and medicinal composition | |
CN1243779C (en) | Hydrophili polymer derirative having Y shaped branch, its preparation method, combined object with medicine molecule and medical compositon containing combined object | |
CN100349963C (en) | Multi-arm polypeptide-poly (ethylene glycol) block copolymers as drug delivery vehicles | |
CN1264858C (en) | Angiogenesis-inhibitory tripeptides, compositions and their methods of use | |
CN1079971A (en) | The D51-7059 of polymer-bound | |
JP4365221B2 (en) | Hydrophilic polymer-product of binding of multicarboxyl oligopeptide and drug molecule, pharmaceutical composition and pharmaceutical use thereof | |
CN1263473A (en) | Composition and method for enhancing transport across biological membranes | |
WO2010131675A1 (en) | Polymer conjugate of bioactive substance having hydroxy group | |
CN1155392C (en) | High-molecular block copolymer-medicine compound preparation | |
JP5856069B2 (en) | Polymer derivatives of novel cytidine antimetabolites | |
EP2042195A1 (en) | Polymer conjugate of combretastatin | |
CN1503664A (en) | Colloidal suspension of nanoparticles based on am amphiphilic copolymer | |
CN1511044A (en) | Elogated and multiple spacers in activatible prodrugs | |
CN1705683A (en) | Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives | |
CN103083680B (en) | Polyethylene glycol (PEG)-amino acid oligopeptide-irinotecan combo and its medicinal composition | |
JP2010523582A5 (en) | ||
JPWO2007111211A1 (en) | Taxane polymer conjugates | |
CN1187199A (en) | Novel dolastatin derivatives, their preparation and use | |
TWI480070B (en) | Conformations of divergent peptides with mineral binding affinity | |
CN1255926A (en) | 20(S) camptothecin glycoconjugates | |
CN1840201A (en) | Polyethylene glycol prodrug of gambogicacid, its preparation method, formulation and use | |
CN1252130C (en) | Hydrophilic polymer and tanshinones medicine conjugation agent and medicine composition containing same | |
CN1709906A (en) | Alpha-intermedin cyclic analog peptide and use thereof | |
CN1252728A (en) | Dolastatin-15 derivatives in combination with taxanes | |
CN1098106C (en) | Anthracycline conjugates, their preparation and their use as antitumor agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20091202 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20110401 Granted publication date: 20090408 Pledgee: Bank of China Limited by Share Ltd. Beijing subbranch Pledgor: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING)|JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Registration number: 2009110000662 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Branched polyglycol-amino acid oligopeptide and its active derivative and medicinal composition Effective date of registration: 20110629 Granted publication date: 20090408 Pledgee: Zhongguancun Beijing science and technology Company limited by guarantee Pledgor: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING)|JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Registration number: 2011990000250 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20120607 Granted publication date: 20090408 Pledgee: Zhongguancun Beijing science and technology Company limited by guarantee Pledgor: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING)|JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Registration number: 2011990000250 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: 124000 Liaoning Province, Panjin city Shuangtaizi District Park Street, South and West No. 2111020090140248 Patentee after: Liaoning Kai Kai Technology Co.,Ltd. Address before: 100085 Haidian District, Beijing on the road to information on the international science and Technology Park, building C, floor four, layer Patentee before: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING) |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090408 |